• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

shankar.siva@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-2840-0658

Prof Shankar Siva

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

553 Scholarly works
8 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications
    DOI: 10.1007/s00345-026-06603-x
  • 2026

    Journal article

    Deep learning and radiomics models in patients with advanced non-small cell lung cancer treated with immunotherapy combined with stereotactic radiotherapy
    DOI: 10.1038/s41598-026-53520-5
  • 2026

    Journal article

    Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
    DOI: 10.1038/s41467-026-74255-x
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    Reducing the Impact of Radiation on the Heart for Cancer and Cardiac Disease Patients
  • 2020

    Research grants (other domestic)

    Stereotactic Ablative Body Radiotherapy (Sabr) as a Catalyst to Improve Outcomes From Immunotherapy
  • 2018

    Journal article

    Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
    DOI: 10.2967/jnumed.117.199554
  • 2018

    Research Grant

    Stereotactic Ablative Radiotherapy (Sabr) as a New Precision Treatment Option in Kidney Cancer
Shankar Siva

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
    DOI: 10.1038/s41467-026-75660-y
  • 2026

    Journal article

    Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era
    DOI: 10.1002/pros.70231
  • 2026

    Journal article

    Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)
    DOI: 10.1136/bmjopen-2026-119811
  • 2026

    Journal article

    Inconsistent definitions of local control for stereotactic body radiation therapy for early-stage lung cancer – A systematic review
    DOI: 10.1016/j.radonc.2026.111695
  • 2026

    Journal article

    Pre-clinical data interpretation requires clinical context
    DOI: 10.1038/s41586-026-10774-3
  • 2026

    Journal article

    A Response to the Letter to the Editor: Radiotherapy to the Primary, With or Without Total Metastatic Ablation
    DOI: 10.1016/j.jtho.2026.103926
  • 2026

    Journal article

    Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial
    DOI: 10.1016/j.euo.2026.01.001

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224